Menu
Search
|

Menu

Close
X

Editas Medicine Inc EDIT.OQ (NASDAQ Stock Exchange Global Select Market)

33.82 USD
-0.97 (-2.79%)
As of Feb 16
chart
Previous Close 34.79
Open 34.84
Volume 401,010
3m Avg Volume 420,117
Today’s High 35.91
Today’s Low 33.78
52 Week High 41.60
52 Week Low 13.13
Shares Outstanding (mil) 41.74
Market Capitalization (mil) 1,043.82
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.38 Mean rating from 8 analysts

KEY STATS

Revenue (mm, USD)
FY17
4
FY16
6
FY15
2
EPS (USD)
FY17
-1.500
FY16
-3.031
FY15
-2.053
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
185.11
5.77
Price to Book (MRQ)
vs sector
5.53
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
26.42
16.52
LT Debt to Equity (MRQ)
vs sector
18.31
12.22
Return on Investment (TTM)
vs sector
-42.42
14.43
Return on Equity (TTM)
vs sector
-63.35
16.13

EXECUTIVE LEADERSHIP

Katrine Bosley
President, Chief Executive Officer, Director, Since 2014
Salary: $450,000.00
Bonus: $222,750.00
Andrew Hack
Chief Financial Officer, Since 2015
Salary: $157,500.00
Bonus: --
Charles Albright
Chief Scientific Officer, Since 2016
Salary: $136,538.00
Bonus: $44,297.00
Gerald Cox
Chief Medical Officer, Since 2016
Salary: $100,000.00
Bonus: --
Andrew Hirsch
Director, Since 2017
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

11 Hurley St
CAMBRIDGE   MA   02141-2110

Phone: +1617.4019000

Editas Medicine, Inc. is a genome editing company. It is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It operates through developing and commercializing genome editing technology segment. It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology. CRISPR uses a protein-ribonucleic acid (RNA) complex composed of an enzyme, including either CRISPR associated protein 9 (Cas9) or CRISPR from Prevotella and Francisella 1 (Cpf1), bound to a guide RNA molecule designed to recognize a particular deoxyribonucleic acid (DNA) sequence. Its platform consists of four components: nuclease engineering, delivery, control and specificity, and directed editing. Its programs include Eye Diseases, Engineered T Cell Therapies for Immuno-Oncology and additional research programs. It is developing a genome editing therapeutic for Leber Congenital Amaurosis type 10 (LCA10).

SPONSORED STORIES